Phase I, Open Label Trial to Explore Safety of Combining BIBW 2992 and Radiotherapy With or Without Temozolomide in Newly Diagnosed GBM

Trial Profile

Phase I, Open Label Trial to Explore Safety of Combining BIBW 2992 and Radiotherapy With or Without Temozolomide in Newly Diagnosed GBM

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Aug 2017

At a glance

  • Drugs Afatinib (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 08 May 2017 Planned End Date changed from 1 Apr 2017 to 29 Sep 2017.
    • 08 May 2017 Planned primary completion date changed from 1 Apr 2017 to 29 Sep 2017.
    • 03 Oct 2016 Planned End Date changed from 1 Oct 2016 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top